ID: ALA5287006

Max Phase: Preclinical

Molecular Formula: C19H14F4N4O

Molecular Weight: 390.34

Associated Items:

Representations

Canonical SMILES:  O=C1NCCc2c1cnn2-c1cc(Cc2cc(F)cc(C(F)(F)F)c2)ccn1

Standard InChI:  InChI=1S/C19H14F4N4O/c20-14-7-12(6-13(9-14)19(21,22)23)5-11-1-3-24-17(8-11)27-16-2-4-25-18(28)15(16)10-26-27/h1,3,6-10H,2,4-5H2,(H,25,28)

Standard InChI Key:  MPYWPSLWTHTDLP-UHFFFAOYSA-N

Associated Targets(Human)

Probable G-protein coupled receptor 52 435 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 390.34Molecular Weight (Monoisotopic): 390.1104AlogP: 3.30#Rotatable Bonds: 3
Polar Surface Area: 59.81Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.96CX Basic pKa: 1.01CX LogP: 3.35CX LogD: 3.35
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.70Np Likeness Score: -1.29

References

1. Poulter S, Austin N, Armstrong R, Barnes M, Bucknell SJ, Higueruelo A, Banerjee J, Mead A, Mould R, MacSweeney C, O'Brien MA, Stott LA, Watson SP..  (2023)  The Identification of GPR52 Agonist HTL0041178, a Potential Therapy for Schizophrenia and Related Psychiatric Disorders.,  14  (4): [PMID:37077397] [10.1021/acsmedchemlett.3c00052]

Source